Armata Pharmaceuticals Advances AP-SA02 to Planned Phase 3 Trial for MRSA/MSSA Bacteremia with FDA Submissions and DoD Funding 123
Armata Pharmaceuticals Announces Key Milestones Supporting P...
Sign in to continue:
Armata Pharmaceuticals Announces Key Milestones Supporting P...
Zurn Elkay Water Solutions Corp Announces Acquisition of Int...
Hut 8 Fully Commercializes 1 GW Beacon Point AI Data Center ...
REGENXBIO Announces \$100 Million Public Offering of Common ...
Dyne Therapeutics, Inc. Files Form 8-K: Key Developments and...
Gates Industrial Corporation Ltd. Files Form 8-K: Redomicili...
Strive, Inc. (NASDAQ: ASST, SATA) Files Form 8-K: Key Update...
VPR Brands, LP. - 8-K Filing Analysis VPR Brands, LP. Fi...
Strategy Inc. (Formerly MicroStrategy): Key Updates from Jul...
MainStreet Bancshares, Inc. Posts Strong Q2 2026 Results: Ne...